NCT01073748

Brief Summary

Asthma is a common inflammatory airway disease. Several researches have demonstrated a possible connection between asthma and exposure to paracetamol. Our hypothesis is that even a single dose of paracetamol is sufficient to cause a measurable change in lung functions. This trial aims to identify a possible effect of single dose paracetamol on lower airway function.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable asthma

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 22, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 23, 2010

Completed
6 days until next milestone

Study Start

First participant enrolled

March 1, 2010

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2011

Completed
Last Updated

January 25, 2011

Status Verified

January 1, 2011

Enrollment Period

1 year

First QC Date

February 22, 2010

Last Update Submit

January 23, 2011

Conditions

Keywords

AsthmaAcetaminophenparacetamolFeNOSpirometryLung function

Outcome Measures

Primary Outcomes (1)

  • A measurable change in lung functions in response to paracetamol exposure.

    1 year

Study Arms (2)

asthmatic subjects

ACTIVE COMPARATOR

Asthmatic children will be randomly exposed to paracetamol and placebo consecutively and their lung functions will be blindly compared.

Drug: paracetamol

Healthy children

OTHER

Children with no asthma as control group.

Drug: paracetamol

Interventions

single dose of paracetamol 15mg/kg.

Also known as: Acetaminophen, Acamol
Healthy childrenasthmatic subjects

Eligibility Criteria

Age7 Years - 16 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • age: 7-16 years
  • research group: children who have been diagnosed as asthmatic according to the American thoracic society (ATS) criteria
  • control group: children who are not known to have asthma

You may not qualify if:

  • paracetamol sensitivity
  • children with any kind of chronic disease (except asthma)
  • children with non asthma related chronic lung disease
  • acute asthma attack
  • children on systemic steroids

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tel Aviv Sourasky Medical Center

Tel Aviv, Israel

RECRUITING

MeSH Terms

Conditions

Asthma

Interventions

Acetaminophen

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • Ruth Soferman, M.D

    TASMC

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Assaf Tsivion, M.D

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

February 22, 2010

First Posted

February 23, 2010

Study Start

March 1, 2010

Primary Completion

March 1, 2011

Last Updated

January 25, 2011

Record last verified: 2011-01

Locations